Safety and outcomes of eculizumab for acetylcholine receptor-positive generalized myasthenia gravis in clinical practice.

Joome SuhVirginia ClarkeAnthony A AmatoAmanda C Guidon

Published in: Muscle & nerve (2022)

Clinical improvement occurred in most patients after eculizumab initiation, beginning as quickly as 1 mo. Steroids were tapered and maintenance IVIG and PLEX were discontinued in most. Eculizumab had a favorable safety profile even when combined with other immunosuppressants.

Keyphrases

myasthenia gravis
clinical practice
end stage renal disease
ejection fraction
newly diagnosed
prognostic factors
type diabetes
insulin resistance
glycemic control